tiprankstipranks
Trending News
More News >
AbbVie (DE:4AB)
XETRA:4AB
Germany Market
Advertisement

AbbVie (4AB) Earnings Dates, Call Summary & Reports

Compare
24 Followers

Earnings Data

Report Date
Oct 24, 2025
Before Open (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
2.79
Last Year’s EPS
2.56
Same Quarter Last Year
Moderate Buy
Based on 19 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Jul 31, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reflects a strong overall performance with significant achievements in revenue growth, pipeline advancement, and strategic acquisitions. However, challenges remain in specific segments such as HUMIRA sales and the aesthetics market.
Company Guidance
During AbbVie's Second Quarter 2025 Earnings Conference Call, the company reported adjusted earnings per share of $2.97, exceeding the guidance midpoint by $0.11. Total net revenues for the quarter were $15.4 billion, surpassing expectations by over $400 million, with significant contributions from Skyrizi and Rinvoq, which together are projected to achieve more than $25 billion in sales this year. The company raised its full-year revenue guidance by $800 million to $60.5 billion and increased its full-year adjusted earnings per share guidance by $0.21 to a range of $11.88 to $12.08. AbbVie highlighted strong double-digit growth in neuroscience and noted progress in its R&D pipeline, including several late-stage program approvals and strategic acquisitions to bolster its future growth.
Strong Financial Performance
Adjusted earnings per share of $2.97, $0.11 above guidance midpoint. Total net revenues were $15.4 billion, exceeding expectations by over $400 million.
Robust Growth in Key Segments
Sales growth of 22% from the ex-HUMIRA platform, with Skyrizi and Rinvoq expected to deliver more than $25 billion in combined sales this year. Neuroscience segment also showed strong double-digit growth driven by Vraylar, Vyalev, and migraine portfolio.
Increased Guidance
Full-year revenue guidance raised by $1.5 billion since the start of the year, now expecting $60.5 billion. Adjusted EPS guidance increased to between $11.88 and $12.08.
Pipeline Advancements
Notable approvals for EMRELIS in non-small cell lung cancer and Rinvoq for GCA. Regulatory submission for TrenibotE in aesthetics and positive Phase III results in alopecia areata.
Strategic Acquisitions and Collaborations
Over 30 business development transactions since last year, including acquisition of Capstan Therapeutics and collaboration with ADARx for siRNA therapies.

AbbVie (DE:4AB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

DE:4AB Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Oct 24, 2025
2025 (Q3)
2.79 / -
2.565
Jul 31, 2025
2025 (Q2)
2.46 / 2.54
2.26612.08% (+0.27)
Apr 25, 2025
2025 (Q1)
2.03 / 2.10
1.9756.49% (+0.13)
Jan 31, 2025
2024 (Q4)
1.81 / 1.85
2.385-22.58% (-0.54)
Oct 30, 2024
2024 (Q3)
2.50 / 2.56
2.5221.69% (+0.04)
Jul 25, 2024
2024 (Q2)
2.19 / 2.27
2.488-8.93% (-0.22)
Apr 26, 2024
2024 (Q1)
1.93 / 1.98
2.103-6.10% (-0.13)
Feb 02, 2024
2023 (Q4)
2.39 / 2.39
3.078-22.50% (-0.69)
Oct 27, 2023
2023 (Q3)
2.45 / 2.52
3.129-19.40% (-0.61)
Jul 27, 2023
2023 (Q2)
2.42 / 2.49
2.881-13.65% (-0.39)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

DE:4AB Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Jul 31, 2025
€166.20€170.00+2.29%
Apr 25, 2025
€157.03€159.81+1.77%
Jan 31, 2025
€165.61€177.59+7.24%
Oct 30, 2024
€170.81€177.76+4.07%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does AbbVie (DE:4AB) report earnings?
AbbVie (DE:4AB) is schdueled to report earning on Oct 24, 2025, Before Open (Confirmed).
    What is AbbVie (DE:4AB) earnings time?
    AbbVie (DE:4AB) earnings time is at Oct 24, 2025, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of AbbVie stock?
          The P/E ratio of AbbVie is N/A.
            What is DE:4AB EPS forecast?
            DE:4AB EPS forecast for the fiscal quarter 2025 (Q3) is 2.79.

              AbbVie (DE:4AB) Earnings News

              ABBV Earnings: AbbVie Rallies Alongside Q4 Beats
              Premium
              Market News
              ABBV Earnings: AbbVie Rallies Alongside Q4 Beats
              7M ago
              ABBV Earnings: AbbVie Reports Strong Q3 Results, Raises Outlook
              Premium
              Market News
              ABBV Earnings: AbbVie Reports Strong Q3 Results, Raises Outlook
              10M ago
              ABBV Earnings: AbbVie Exceeds Q2 Expectations Driven by Strong Immunology Sales
              Premium
              Market News
              ABBV Earnings: AbbVie Exceeds Q2 Expectations Driven by Strong Immunology Sales
              1y ago
              AbbVie (NYSE:ABBV) Sinks as Humira Drug Sees Increased Competition
              Premium
              Market News
              AbbVie (NYSE:ABBV) Sinks as Humira Drug Sees Increased Competition
              1y ago
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis